TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02393014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple physical exercises
Description: 1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple physical exercises
Description: 1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple physical exercises
Description: 1. The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~2. The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~3. The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not.
Study: NCT02114788

Intervention type: OTHER
Intervention: Internet-based
Study: NCT02007733

Intervention type: OTHER
Intervention: Serial Weights
Description: We will collect serial weights on all children enrolled in this study.

Intervention type: OTHER
Intervention: Serial Weights
Description: We will collect serial weights on all children enrolled in this study.

Intervention type: OTHER
Intervention: IVC/Aorta Ultrasound
Description: We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.

Intervention type: OTHER
Intervention: Clinical Assessment
Description: We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.

Intervention type: OTHER
Intervention: Clinical Assessment
Description: We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
Study: NCT01051349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab)
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent seasonal influenza vaccine
Description: All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
Study: NCT00611676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
Study: NCT01968551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: 800 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: 800 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline DRV- containing ARV regimen
Description: Participants will take their baseline DRV- containing ARV regimen as prescribed.
Study: NCT01916239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard pomegranate extract formulation
Description: Standard pomegranate extract formulation containing 20% punicalagin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract formulation-1
Description: New pomegranate extract formulation-1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract formulation-2
Description: New pomegranate extract formulation-2
Study: NCT01769898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol-budesonide
Description: Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol-budesonide
Description: Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
Study: NCT01842178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scratching
Description: Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scratching
Description: Endometrial Injury~* Done between 18-24 days prior to embryo transfer cycle.~* Using transfer catheter.~* Introduction of the same to the uterine fundus.~* Systematic scrapping of the four uterine walls, lengthwise.~* Performed by a skilled doctor.~* Subsequent ultrasound control.
Study: NCT04169347

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: 2 week cycles
Study: NCT04551339

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PreserVision AREDS formulation soft gels or tablets
Description: Two tabs taken daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin with 11mg of zinc
Description: One tab taken daily for three months
Study: NCT03374618

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
Study: NCT00863460

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: cranial radiotherapy
Description: 40 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive chemotherapy and hematopoietic stem cell rescue
Description: intensive chemotherapy and hematopoietic stem cell rescue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX based chemotherapy
Description: R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX based chemotherapy
Description: R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58\&59 and days79\&80
Study: NCT03426007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
Study: NCT03374618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
Study: NCT02112955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke self-management program
Description: A nurse-led community-based self-efficacy enhancing stroke self-management program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care such as hospital-based or community-based health education or services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care such as hospital-based or community-based health education or services.
Study: NCT03796130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery
Study: NCT01432210

Intervention type: OTHER
Group type: OTHER
Intervention: Post-prandial Feeding Study

Intervention type: OTHER
Group type: OTHER
Intervention: Post-prandial Feeding Study
Study: NCT04178356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Training
Description: The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
Study: NCT00760084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
Study: NCT03229460

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard low flow therapy
Description: In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
Study: NCT01769898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 0.1 Q12H
Study: NCT03229460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal oxygen therapy
Description: The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 \>92%.
Study: NCT01769898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for theophylline 0.1 Q12H
Study: NCT03172286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequencer
Description: Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequencer
Description: Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
Study: NCT03164460

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT/IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Undergo IMRT/IMPT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT00454142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies
Study: NCT03342859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan, BAY1002670
Description: Daily single oral doses of 2 mg vilaprisan over 8-12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Daily single oral doses of 5 mg ulipristal over 8-12 weeks
Study: NCT02887599

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection
Description: 1ml of blood specimen collection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood collection
Description: 1ml of blood specimen collection
Study: NCT03229460

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: association of high flow nasal oxygen therapy and non invasive positive pressure ventilation
Description: The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 \>92% with the minimal FiO2.
Study: NCT02145702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Care Dialysis
Description: 12 weeks of standard of care.
Study: NCT00677430

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A brief questionnaire packet will be completed.

Intervention type: PROCEDURE
Intervention: Digital Imaging
Description: Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
Study: NCT03160196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System
Description: It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
Study: NCT04531072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir 300/100 mg
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Study: NCT00555789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: 200mg oral b.i.d.
Study: NCT05840705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small curved incision with apex lateral
Description: Small curved incision with apex lateral
Study: NCT00521963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intraarticular injection of infliximab
Description: A single injection of 100 mg of infliximab
Study: NCT01450137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab + Glucocorticoids (GCs)
Description: Tocilizumab 8mg/kg every 4 weeks until week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Glucocorticoids (GCs)
Description: Placebo every 4 weeks until week 52.
Study: NCT03580447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus extract
Description: Citrus extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT03160196

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care based on clinical practice guideline
Description: It is about usual care aligned with the diabetes guideline.
Study: NCT03231150

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Steroid Injection into the plantar heel
Description: Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Steroid Injection into the plantar heel
Description: Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Injection
Description: Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Guided injection
Description: Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
Study: NCT00695201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine, Oxaliplatin, CPT-11
Description: For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine, Oxaliplatin, CPT-11
Description: For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
Study: NCT01834859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient program
Description: Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient lifestyle program
Description: Diet (phase 1) and lifestyle intervention (phase 2)
Study: NCT02314143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
Study: NCT03420053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: 0.9% sodium chloride solution
Study: NCT02314143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
Study: NCT04344743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation without contrast
Description: Cryoballoon ablation without contrast
Study: NCT00004229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Study: NCT01291875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal treatment
Description: Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supragingival biofilm control
Description: Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
Study: NCT02383485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Heart rate monitors worn by each child at each session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After-school program
Description: Supervised recreational program with token economy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After-school program
Description: Supervised recreational program with token economy